PAI-1 Antibodies

Santa Cruz Biotechnology features a diverse variety of PAI-1 monoclonal antibodies for various research applications. PAI-1 Antibodies are optimized for techniques such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Plasminogen activator inhibitor-1 (PAI-1) plays a critical role in the regulation of fibrinolysis, the process that prevents blood clots from growing and becoming problematic. By inhibiting tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), PAI-1 is essential for maintaining hemostatic balance. PAI-1 has been linked to various pathological conditions, including cardiovascular diseases and cancer. Research has shown that PAI-1 expression levels can serve as biomarkers for disease progression and treatment response. Understanding PAI-1's molecular mechanisms and signaling pathways continues to reveal new therapeutic opportunities. Investigating PAI-1's role in different biological processes helps identify novel drug targets and treatment strategies. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of PAI-1's role in human health and disease.